– Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023 – TORONTO, June 15, 2023 /PRNewswire/ – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes-focused life sciences company developing the first…